- Nanoform and Takeda to collaborate on plasma-derived therapy formulations.
- First in vivo study results expected by early 2025.
Nanoform Finland has announced a pre-clinical development agreement with the plasma-derived therapies business unit of Takeda to develop new formulations for the treatment of rare conditions. This collaboration will leverage Nanoform’s nanoforming technology to enhance the performance of plasma-derived therapies.
Under the agreement, Nanoform will first conduct in vitro proof of concept studies. Following these studies, Nanoform will provide non-GMP nanomaterials to Takeda for in vivo testing, with the initial results anticipated by early 2025. This project aligns with Nanoform’s business model, with the value estimated between €0.05m and €0.5m per non-GMP project.
Edward Haeggström, CEO of Nanoform, stated, “Direct nanoforming of biologics is a promising new approach to allow more life-changing large-molecule medicines to reach the market. We look forward to entering in vivo studies together with Takeda and expanding our already very positive relationship.”
The partnership aims to advance these medicine candidates to clinical stages and eventually bring them to market, potentially offering new treatment options for patients with rare diseases. Nanoform’s technology, which can deliver large-molecule drug particles of tuneable size and morphology, will play a key role in this development, providing the opportunity to tailor drug release profiles and explore novel delivery routes.
Overview of outsourcing trends 
